Alcaftadine

CHEMBL1201747 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
307.4 g/mol
LogP
1.7
Phase
4

An antihistamine eye drop that blocks histamine receptors in the eye and also stabilizes mast cells to prevent the release of allergy-triggering chemicals, providing rapid and sustained relief from itchy, allergic eyes. It is specifically formulated for the conjunctiva and works effectively to reduce redness, itching, and watering associated with allergic conjunctivitis.

分子量

307.4000 g/mol

LogP

1.70

TPSA

38.10 Ų

Lipinski 五规则

符合

作用机制

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1

InChI

InChI=1S/C19H21N3O/c1-21-9-6-15(7-10-21)18-17-5-3-2-4-14(17)8-11-22-16(13-23)12-20-19(18)22/h2-5,12-13H,6-11H2,1H3

Molecular Formula

C19H21N3O

HBD / HBA

- / 3

可旋转键数

1

重原子数

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

An antihistamine eye drop that blocks histamine receptors in the eye and also stabilizes mast cells to prevent the release of allergy-triggering chemicals, providing rapid and sustained relief from itchy, allergic eyes. It is specifically formulated for the conjunctiva and works effectively to reduce redness, itching, and watering associated with allergic conjunctivitis.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Alcaftadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201747. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 19371515. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.